Trial Profile
A Phase 2b Open-Label Single Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors HUYA Bioscience International
- 08 Jun 2022 Status changed from active, no longer recruiting to completed.
- 09 Dec 2021 Planned End Date changed from 1 Dec 2020 to 1 Jun 2022.
- 09 Dec 2021 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2022.